LITMIR.BIZ

Скачать книгу

of him, tapped out a rhythmless tune. Time for more medication? Warren wondered. As if noticing Jones’ scrutiny, Tompkinson clasped his hands together tightly, arresting the tremors.

      “You’d need to speak to them, I would imagine. Personnel can give you the details of all the current and former members of the lab. As to whether any still bear a grudge, that’s hard to say. He did have two technicians speak to their unions about a constructive dismissal case concerning alleged bullying. However they decided not to pursue the case after finding better-compensated work elsewhere in the department.”

      “You bought them off?”

      Tompkinson’s shrug was non-committal. “They found a better position and decided it wasn’t worth their time and effort to pursue the case.”

      I’ll bet the unions were annoyed about that! thought Jones, but said nothing.

      “I believe that he also had run-ins with some of his other graduate students, although nothing serious enough to cross my desk.”

      Jones made a quick note to get onto Personnel and Student Services to find out their details. His list of potential suspects and people to interview was growing longer and longer.

      Karen Hardwick had remained silent throughout most of the interview, but Jones could see that she had been paying close attention.

      “What will happen to Professor Tunbridge’s research group, now that he is gone?”

      “A tricky question. This has never really happened before. A few years ago a young Principal Investigator was tragically killed on holiday. However, he only had a single PhD student and a research technician. The student moved into another lab, taking enough of the lab’s funding to complete his project. The research technician was also redeployed and the research group was wound up. It was a bit messy for a few weeks, but it all sorted itself out.

      “Alan’s lab is another matter. For a start it’s much larger and it has rather a lot of allocated funding. I suppose there will have to be a meeting of all of those concerned. In the interim at least, the lab will probably continue running under Mark Crawley. The students will be dealt with on a case-by-case basis — some may go and work in different laboratories with like-minded research groups, others may continue to work with Mark. As to the long-term, the funding agencies and the university will have to decide what happens.”

      So, it seemed as though Crawley might be the heir apparent to the research group after all. Would he want it, though, or would it be, as he’d claimed, a weight of responsibility he could do without? A point for future consideration, Jones decided.

      “Well, thank you for your time, Professor. We may need to ask you a few more questions in the future. In the meantime, could you speak to your Personnel and Student Services department and let them know that we will be asking to see your records?”

      “Of course. I suspect I’ll be in here all day if you want to contact me. But I’m surprised that you are leaving so soon.”

      Jones blinked in surprise. “I’m not sure I see what you are getting at.”

      “Well, it would seem that you have missed the most obvious motive, Chief Inspector.”

      “Oh? What might that be, then?”

      “Well, money, of course.”

      Jones blinked in surprise.

      “Money? How would killing Professor Tunbridge make his killer rich? Was Professor Tunbridge particularly wealthy?”

      “No, at least not that I know of. However, Alan’s work was potentially very lucrative.”

      “So, tell me about Professor Tunbridge’s research and why you think it provides a motive.”

      Tompkinson took off his glasses and polished them again, before replacing them and resuming his ‘teacher pose’.

      “Where to start? OK, to fully appreciate how big a motive this is, you need to understand some basic science. I’m sure that you’ve heard about the problems with bacteria becoming resistant to antibiotics? So-called ‘hospital superbugs’ such as MRSA, resistant to even the strongest of antibiotics?” Jones and Hardwick both nodded.

      “Well, the problem cannot be over-stated. There are strains of Staphylococcus aureus, the bacterium that MRSA stems from, that are resistant to all commonly used antibiotics, even the so-called ‘last resort’ drugs such as vancomycin. Let me be clear, here. If you develop an infection from this strain of bacteria, you will die. And it’s not just hospital superbugs. Extreme Drug-Resistant Tuberculosis, or XDRTB, is now being seen in TB hotspots around the globe. The current vaccination against TB, the BCG, is woefully poor and it’ll be years before the latest version comes online. TB is spread by coughing and sneezing. Regular TB still kills millions of people each year. Without antibiotics to kill off the infection, the death rate will soar. These days, a person with TB can pick it up on one side of the world and cough and sneeze his way across the globe in twenty-four hours, infecting everyone he comes in contact with. Can you imagine what it would be like if the strain that the person was carrying was XDRTB?”

      Jones tried to imagine such a scenario and felt a cold chill sweep over him.

      “Of course, drug companies are trying to develop new antibiotics as we speak. however the speed at which bacteria can become resistant to these drugs is frightening. Did you know that the first antibiotic, penicillin, was first used to treat patients in the 1940s yet within four years cases of resistant bacteria were reported? By the 1960s it was present in hospitals and by the end of the 1990s almost forty per cent of Staphylococcus bacteria were resistant. Since penicillin’s discovery, dozens of different antibiotics have been discovered — almost all of which are now resisted by bacteria. Some of those antibiotics were rendered all but useless within ten years. Because of that, there is actually less incentive for drugs companies to invest in new antibiotics.”

      “Huh? You’ve lost me, Professor. Surely with such a need for new antibiotics, whoever discovers a new one stands to make a fortune!”

      Tompkinson smiled sadly. “Unfortunately, it doesn’t work like that. It takes up to a billion US dollars and anything up to fifteen years to develop a new drug. The success rate from good idea to pharmacy counter is tiny. The vast majority of potential drugs are eliminated in the early stages of development because they don’t work or have unacceptable side effects. Drug research is an incredible gamble, with the pay-off being massive exclusive sales in the years before the patent expires after which everyone and his uncle can use your research to make your drug at a fraction of the cost and undercut you. Because of that, pharmaceutical firms favour drugs that will recoup that investment. They like to play safe. So what’s the point of spending a billion dollars developing a new antibiotic that ninety per cent of bugs are going to be resistant to before you’ve even made your investment back?”

      The question hung in the air.

      Scratching his head and trying to keep up, Jones asked the obvious.

      “So where is the motive, then? Presumably anyone stealing his idea would still have to spend millions doing the safety trials. I don’t know much about this sort of thing, but I seem to recall from an article in some Sunday supplement that the bulk of the cost of developing a drug lies with the safety testing. Who is going to murder the prof over something that won’t make them any money?”

      The professor nodded.

      “You are quite right, of course. As regards the bacteria acquiring resistance, rumour has it Professor Tunbridge had solved that particular conundrum.”

      “He’s developed a multi-pronged attack to delay the onset of antibiotic resistance, hasn’t he?”

      The question was blurted out from DC Hardwick.

      Tompkinson nodded enthusiastically as if praising a favourite student.

      “Very good. I see that you know something about this, Constable. Did you study at university before joining the police?”

      She

Скачать книгу